CXCL12 and osteosarcoma: In support, Huang et al. observed that pre-treatment of osteosarcoma cells with plerixafor attenuated the CXCL12-induced increase in NF-kB promoter activity [53], with similar results reported for oral squamous cell carcinoma [54].